1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Rebus Holdings, Inc.

Rebus Holdings, Inc.

RBSH
Rebus Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
3,213.00Market Cap
Rebus Holdings, Inc.
RBSH
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-76,799.89
-369,584.56
-570,314.11
-425,783.9
-476,166.67
-532,307.69
-331,375
-368,105.26
-245,250
-132,791.67
-57,512.95
-7.98
-298.98
-10.89
0.35
-0.03
0.02
Basic EPS, GAAP
-8,669.78
-314,905
-225,146.22
-277,921.7
-312,000
-348,307.69
-294,687.5
-265,684.21
-193,208.33
-114,041.67
-5,673.58
-135.73
-100.19
-0.65
-0.09
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-160,120.11
-529,666.33
-1,132,220.22
-1,444,760.8
-1,680,083.33
-2,083,153.85
-2,023,875
-2,072,421.05
-1,886,041.67
-2,026,416.67
-309,497.41
-39,750.5
-19,423.82
-115.89
-8.41
-2.05
-2.04
Book Value per Share
46,306.78
-1,942.22
-23,506.11
111,589.1
241,833.33
-66,461.54
71,375
-210.53
-83,000
-39,833.33
-46,103.63
-5,522.29
-2,792.25
-21.64
-0.66
-0.16
-0.17
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
8
32
32
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-3
-5
-4
-6
-7
-5
-7
-6
-3
-11
- -
-1
-6
3
-1
1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
- -
2
3
5
-1
1
- -
-2
-1
-9
-8
-9
-13
-5
-5
-6
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
1
3
-1
1
- -
-2
-1
-9
-8
-9
-13
-5
-5
-6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-5.87
- -
-0.9
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
6
6
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-160.27%
-2.65%
4.28%
Free Cash Flow
-1.92%
15.74%
1.88%
Net Income, GAAP
807.19%
1,575.35%
-137.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-3.64
2.48
0.8
- -
0.35
2022
-0.02
-0.04
0.01
- -
-0.03
2023
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Halozyme Therapeutics, Inc. (0J2O.L)
Valbiotis S.A. (ALVAL.PA)
GeoVax Labs, Inc. (GOVX)
Palatin Technologies, Inc. (PTN)
Photocure ASA (0IMT.L)
Sequenom Inc. (SQNM)
Business
Rebus Holdings, Inc. (RBSH) is a clinical-stage biotechnology company focused on the research, development, and commercialization of precision therapeutics targeting the tumor microenvironment to treat cancer; its pipeline centers on adenosine receptor modulators delivered via proprietary nano- or microparticle formulations for intratumoral administration. Core assets include RT-AR001, the lead candidate comprising an A2A adenosine receptor antagonist in nanoparticle form to enhance tumor infiltration and immune response; additional pipeline components encompass selective A2B antagonists, dual A2A/A2B antagonists, and complementary A2A agonists, all aimed at overcoming immunosuppression in solid tumors. The company operates in the immuno-oncology segment of the healthcare industry, targeting oncologists, hospitals, and strategic partners in North America with plans for global expansion; founded in 2003 and headquartered at 2629 Townsgate Road, Suite 215, Westlake Village, California, it employs a lean model with one full-time equivalent and outsources manufacturing to GMP-compliant contract organizations. In October 2021, Rebus Holdings completed a holding company reorganization from Inspyr Therapeutics, Inc., adopting the RBSH ticker and rebranding its website to rebus-corp.com while reacquiring intellectual property rights including US Patent 9,593,118 covering A2A/A2B antagonists following termination of its licensing agreement with Ridgeway Therapeutics; between September 2021 and February 2022, it manufactured GMP-grade RT-AR001 and A2A antagonists sufficient for IND-enabling studies and initial clinical trials, advancing toward an expected IND submission. The company remains pre-revenue with no recent funding rounds, acquisitions, or partnerships disclosed as of late 2025, concentrating efforts on pipeline characterization and clinical candidate selection led by CEO Raul Silvestre.